Compare CRNC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | BNTC |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.6M | 313.9M |
| IPO Year | 2019 | 2020 |
| Metric | CRNC | BNTC |
|---|---|---|
| Price | $8.90 | $8.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $10.75 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 647.1K | 192.6K |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $24.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $8.51 |
| 52 Week High | $13.28 | $16.76 |
| Indicator | CRNC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 31.76 |
| Support Level | $7.64 | $8.52 |
| Resistance Level | $9.19 | $14.09 |
| Average True Range (ATR) | 0.35 | 0.64 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 75.53 | 22.04 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.